Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane-Reference-Cited by-同舟云学术

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

Published:2013-03 Issue:3 Volume:24 Page:674-679
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Guerrero A.,Gavilá J.,Folkerd E.,Ortiz B.,Martínez F.,García A.,Climent M.A.,Guillem V.,Ruíz A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/3/674/13788667/mds464.pdf

Reference22 articles.

1. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer;Burstein;J Clin Oncol,2010

2. Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer;Goldhirsch;Ann Oncol,2011

3. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study;Geisler;J Clin Oncol,2002

4. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women;Dunbier;J Clin Oncol,2010

5. Letrozole for ovulation induction and controlled ovarian hyperstimulation;Pritts;Curr Opin Obstet Gynecol,2010

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy;npj Breast Cancer;2024-08-01

2. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial;Breast Cancer Research and Treatment;2024-06-28

3. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-03

4. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-12

5. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies;Geburtshilfe und Frauenheilkunde;2023-09